Challenges for a universal staphylococcus aureus vaccine

Clinical Infectious Diseases

Volumn 54, Issue 8, 2012, Pages 1179-1186

  Goldstein, Ellie J C ^a   Proctor, Richard A ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HEMOLYSIN; HLA ANTIBODY; IMMUNOGLOBULIN G; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23 ANTIBODY; MONOCLONAL ANTIBODY; PANTON VALENTINE LEUKOCIDIN; PREDNISONE; STAPHYLOCOCCUS TOXIN; STAPHYLOCOCCUS VACCINE; STAT3 PROTEIN; SUPERANTIGEN; TOLL LIKE RECEPTOR; VIRULENCE FACTOR;

ACTIVE IMMUNIZATION; ANTIBODY PRODUCTION; B LYMPHOCYTE; BACTERIAL ARTHRITIS; CANDIDIASIS; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); COMBINED IMMUNODEFICIENCY; DRUG EFFICACY; DRUG MEGADOSE; GAMMA DELTA T LYMPHOCYTE; GENETIC VARIABILITY; HAEMOPHILUS INFLUENZAE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPER IGE SYNDROME; IMMUNE DEFICIENCY; INNATE IMMUNITY; LETHAL DOSE; LUNG INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; NATURAL KILLER T CELL; NONHUMAN; OPSONIZATION; PASSIVE IMMUNIZATION; PHAGOCYTE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPIC VARIATION; PNEUMONIA; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STAPHYLOCOCCAL SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TH17 CELL;

ANTIBODIES, BACTERIAL; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; HUMANS; INTERLEUKIN-17; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS; TH17 CELLS; TREATMENT FAILURE;

EID: 84859074087     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis033     Document Type: Review

References (85)

1. Soriano A, Martinez JA, Mensa J, et al. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin Infect Dis 2000; 30:368-73.
2. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a metaanalysis. Clin Infect Dis 2003; 36:53-9.
3. Kaye KS, Anderson DJ, Choi Y, Link K, Thacker P, Sexton DJ. The deadly toll of invasive methicillin-resistant Staphylococcus aureus infection in community hospitals. Clin Infect Dis 2008; 46:1568-77.
4. de Kraker ME, Wolkewitz M, Davey PG, Grundmann H. Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother 2011; 55:1598-605.
5. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298:1763-1.
6. Harro JM, Peters BM, O'May GA, et al. Vaccine development in Staphylococcus aureus: taking the biofilm phenotype into consideration. FEMS Immunol Med Microbiol 2010; 59:306-23.
7. Harrison CJ. Innate immunity as a key element in host defense against methicillin resistant Staphylococcus aureus. Minerva Pediatr 2009; 61:503-14.
8. Middleton JR. Staphylococcus aureus antigens and challenges in vaccine development. Expert Rev Vaccines 2008; 7:805-15.
9. Pereira UP, Oliveira DG, Mesquita LR, Costa GM, Pereira LJ. Efficacy of Staphylococcus aureus vaccines for bovine mastitis: a systematic review. Vet Microbiol 2011; 148:117-24.
10. Projan SJ, Nesin M, Dunman PM. Staphylococcal vaccines and immunotherapy: to dream the impossible dream? Curr Opin Pharmacol 2006; 6:473-9.
11. Schaffer AC, Lee JC. Staphylococcal vaccines and immunotherapies. Infect Dis Clin North Am 2009; 23:153-71.
12. Proctor RA. Is there a future for a Staphylococcus aureus vaccine? Vaccine 2011. [In press].
13. Seale A, Finn A. What is the best way to use conjugate vaccines? Curr Opin Infect Dis 2011; 24:219-24.
14. Lowy FD. Medical progress-Staphylococcus aureus infections. N Engl J Med 1998; 339:520-32.
15. Shinefield H, Black S, Fattom A, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002; 346:491-6.
16. DeJonge M, Burchfield D, Bloom B, et al. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J Pediatr 2007; 151:260-5.
17. Patti JM. A humanized monoclonal antibody targeting Staphylococcus aureus. Vaccine 2004; 22(Suppl 1):S39-43.
18. Weems J, Steinberg J, Filler S, et al. Veronate human polyclonal IgG with high anti-S. aureus and anti-polyclonal antibodies tested in neonates. Antimicrob Agents Chemother 2006; 50:2751-5.
19. Benjamin DK, Schelonka R, White R, et al. A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. J Perinatol 2006; 26:290-5.
20. Rupp ME, Holley HP Jr, Lutz J, et al. Phase II, randomized, multicenter, doubleblind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007; 51:4249-54.
21. Weisman LE. Antibody for the prevention of neonatal noscocomial staphylococcal infection: a review of the literature. Arch Pediatr 2007; 14(Suppl 1):S31-4.
22. Burnie JP, Matthews RC, Carter T, et al. Identification of an immunodominant ABC transporter in methicillin-resistant Staphylococcus aureus infections. Infect Immun 2000; 68:3200-9.
23. Garmory HS, Titball RW. ATP-binding cassette transporters are targets for the development of antibacterial vaccines and therapies. Infect Immun 2004; 72:6757-63.
24. Holland SM. Chronic granulomatous disease. Clin Rev Allergy Immunol 2010; 38:3-10.
25. Roos D, Kuhns DB, Maddalena A, et al. Hematologically important mutations: X-linked chronic granulomatous disease (third update). Blood Cells Mol Dis 2010; 45:246-65.
26. Bruton OC. Agammaglobulinemia. Pediatrics 1952; 9:722-8.
27. Winkelstein JA, Marino MC, Lederman HM, et al. X-linked agammaglobulinemia-report on a United States registry of 201 patients. Medicine (Baltimore) 2006; 85:193-202.
28. Miller LS, Cho JS. Immunity against Staphylococcus aureus cutaneous infections. Nat Rev Immunol 2011; 11:505-18.
29. de Beaucoudrey L, Puel A, Filipe-Santos O, et al. Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J Exp Med 2008; 205:1543-50.
30. Ma CS, Chew GY, Simpson N, et al. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med 2008; 205: 1551-7.
31. Milner JD, Brenchley JM, Laurence A, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008; 452:773-6.
32. Minegishi Y, Karasuyama H. Defects in Jak-STAT-mediated cytokine signals cause hyper-IgE syndrome: lessons from a primary immunodeficiency. Int Immunol 2009; 21:105-12.
33. Iwakura Y, Nakae S, Saijo S, Ishigame H. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunological Rev 2008; 226:57-79.
34. Ishigame H, Kakuta S, Nagai T, et al. Differential roles of interleukin-17A and-17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 2009; 30:108-19.
35. Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011; 332:65-8.
36. Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 2010; 10:479-89.
37. Nembrini C, Marsland BJ, Kopf M. IL-17-producing T cells in lung immunity and inflammation. J Allergy Clin Immunol 2009; 123: 986-94.
38. Ardura MI, Banchereau R, Mejias A, et al. Enhanced monocyte response and decreased central memory T cells in children with invasive Staphylococcus aureus infections. PLoS One 2009; 4:e5446.
39. Eyerich K, Foerster S, Rombold S, et al. Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22. J Invest Dermatol 2008; 128: 2640-5.
40. McLoughlin RM, Lee JC, Kasper DL, Tzianabos AO. IFN-gamma regulated chemokine production determines the outcome of Staphylococcus aureus infection. J Immunol 2008; 181:1323-32.
41. Ryan KR, Hong M, Arkwright PD, et al. Impaired dendritic cell maturation and cytokine production in patients with chronic mucocutanous candidiasis with or without APECED. Clin Exp Immunol 2008; 154:406-14.
42. Minegishi Y, Saito M, Nagasawa M, et al. Molecular explanation for the contradiction between systemic Th17 defect and localized bacterial infection in hyper-IgE syndrome. J Exp Med 2009; 206: 1291-301.
43. Fischer A. Human immunodeficiency connecting STAT3, Th17 and human mucosal immunity. Immunol Cell Biol 2008; 86: 549-51.
44. Cho JS, Pietras EM, Garcia NC, et al. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J Clin Invest 2010; 120:1762-73.
45. David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev 2010; 23:616-87.
46. Glikman D, Siegel JD, David MZ, et al. Complex molecular epidemiology of methicillin-resistant Staphylococcus aureus isolates from children with cystic fibrosis in the era of epidemic communityassociated methicillin-resistant S. aureus. Chest 2008; 133:1381-7.
47. Crum-Cianflone N, Weekes J, Bavaro M. Recurrent communityassociated methicillin-resistant Staphylococcus aureus infections among HIV-infected persons: incidence and risk factors. AIDS Patient Care STDS 2009; 23:499-502.
48. Manfredi R, Calza L, Chiodo F. Epidemiology and microbiology of cellulitis and bacterial soft tissue infection during HIV disease: a 10-year survey. J Cutan Pathol 2002; 29:168-72.
49. Mathews WC, Caperna JC, Barber RE, et al. Incidence of and risk factors for clinically significant methicillin-resistant Staphylococcus aureus infection in a cohort of HIV-infected adults. J Acquir Immune Defic Syndr 2005; 40:155-60.
50. Milner JD, Sandler NG, Douek DC. Th17 cells, Job's syndrome and HIV: opportunities for bacterial and fungal infections. Curr Opin HIV AIDS 2010; 5:179-83.
51. Popovich KJ,Weinstein RA, Aroutcheva A, Rice T,Hota B. Communityassociated methicillin-resistant Staphylococcus aureus and HIV: intersecting epidemics. Clin Infect Dis 2010; 50:979-87.
52. Gjertsson I, Hultgren OH, Stenson M, Holmdahl R, Tarkowski A. Are B lymphocytes of importance in severe Staphylococcus aureus infections? Infect Immun 2000; 68:2431-4.
53. Gjertsson I, Nitschke L, Tarkowski A. The role of B cell CD22 expression in Staphylococcus aureus arthritis and sepsis. Microbes Infect 2004; 6:377-82.
54. Lin L, Ibrahim AS, Xu X, et al. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 2009; 5:e1000703.
55. Spellberg B, Ibrahim AS, Yeaman MR, et al. The antifungal vaccine derived from the recombinant n terminus of Als3p protects mice against the bacterium Staphylococcus aureus. Infect Immun 2008; 76:4574-80.
56. Narita K, Hu DL, Mori F, et al. Role of interleukin-17A in cellmediated protection against Staphylococcus aureus infection in mice immunized with the fibrinogen-binding domain of clumping factor A. Infect Immun 2010; 78:4234-42.
57. Kudva A, Scheller EV, Robinson KM, et al. Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in mice. J Immunol 2011; 186:1666-74.
58. Martin FJ, Gomez MI, Wetzel DM, et al. Staphylococcus aureus activates type I IFN signaling in mice and humans through the Xr repeated sequences of protein A. J Clin Invest 2009; 119:1931-9.
59. Brar NK, Niederman MS. Management of community-acquired pneumonia: a review and update. Ther Adv Respir Dis 2011; 5:61-78.
60. Schmaler M, Jann N, Ferracin F, Landmann R. T and B cells are not required for clearing Staphylococcus aureus in systemic infection despite a strong TLR2-MyD88-dependent T cell activation. J Immunol 2011; 186:443-52.
61. Mele T, Madrenas J. TLR2 signalling: at the crossroads of commensalism, invasive infections and toxic shock syndrome by Staphylococcus aureus. Int J Biochem Cell Biol 2010; 42:1066-71.
62. Dunne A, Ross PJ, Pospisilova E, et al. Inflammasome activation by adenylate cyclase toxin directs Th17 responses and protection against Bordetella pertussis. J Immunol 2010; 185:1711-19.
63. Ginsburg I. Role of lipoteichoic acid in infection and inflammation. Lancet Infect Dis 2002; 2:171-9.
64. Hruz P, Zinkernagel AS, Jenikova G, et al. NOD2 contributes to cutaneous defense against Staphylococcus aureus through alphatoxin-dependent innate immune activation. Proc Natl Acad Sci USA 2009; 106:12873-8.
65. Niebuhr M, Gathmann M, Scharonow H, et al. Staphylococcal alpha-toxin is a strong inducer of interleukin-17 in humans. Infect Immun 2011; 79:1615-22.
66. Bestebroer J, de Haas CJ, van Strijp JA. How microorganisms avoid phagocyte attraction. FEMS Microbiol Rev 2010; 34:395-414.
67. Laarman A, Milder F, van Strijp J, Rooijakkers S. Complement inhibition by gram-positive pathogens: molecular mechanisms and therapeutic implications. J Mol Med (Berl) 2010; 88:115-20.
68. Serruto D, Rappuoli R, Scarselli M, Gros P, van Strijp JA. Molecular mechanisms of complement evasion: learning from staphylococci and meningococci. Nat Rev Microbiol 2010; 8:393-9.
69. Duan Z, Pan F, Zeng Z, et al. Interleukin-23 receptor genetic polymorphisms and ankylosing spondylitis susceptibility: a metaanalysis. Rheumatol Int 2011; 31:1796-77.
70. Verkaik NJ, Lebon A, de Vogel CP, et al. Induction of antibodies by Staphylococcus aureus nasal colonization in young children. Clin Microbiol Infect 2010; 16:1312-17.
71. Verkaik NJ, Boelens HA, de Vogel CP, et al. Heterogeneity of the humoral immune response following Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2010; 29:509-18.
72. Ebert T, Smith S, Pancari G, et al. A fully human monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (IsdB) with functional activity in vitro and in vivo. Hum Antibodies 2010; 19:113-28.
73. Ebert T, Smith S, Pancari G, et al. Development of a rat central venous catheter model for evaluation of vaccines to prevent Staphylococcus epidermidis and Staphylococcus aureus early biofilms. Hum Vaccin 2011; 7:603-8.
74. Brown M, Kowalski R, Zorman J, et al. Selection and characterization of murine monoclonal antibodies to Staphylococcus aureus iron-regulated surface determinant B with functional activity in vitro and in vivo. Clin Vaccine Immunol 2009; 16:1095-104.
75. Kuklin NA, Clark DJ, Secore S, et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect Immun 2006; 74:2215-23.
76. Stranger-Jones YK, Bae T, Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci USA 2006; 103:16942-7.
77. Kim HK, DeDent A, Cheng AG, et al. IsdA and IsdB antibodies protect mice against Staphylococcus aureus abscess formation and lethal challenge. Vaccine 2010; 28:6382-92.
78. Harro C, Betts R, Orenstein W, et al. Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humans. Clin Vaccine Immunol 2010; 17: 1868-74.
79. Harro C, Betts RF, Hartzel JS, et al. The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): Results of two Phase I studies. Vaccine 2012 (In press).
80. Joshi A, Pancari G, Smith S, Cope L, McNeely T. Immunization with Staphylococcus aureus iron regulated surface determinant B (IsdB) confers protection via Th17/IL17 pathway in a murine sepsis model. Hum Vaccines Immunotherapeutics 2012; 8; In press.
81. Pepper M, Linehan JL, Pagan AJ, et al. Different routes of bacterial infection induce long-lived TH1 memory cells and short-lived TH17 cells. Nat Immunol 2010; 11:83-9.
82. Sheagren JN. Staphylococcal infections of the skin and skin structures. Cutis 1985; 36:2-6.
83. Sreeramoju P, Porbandarwalla NS, Arango J, et al. Recurrent skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus requiring operative debridement. Am J Surg 2011; 201:216-20.
84. Roehr B. Whooping cough outbreak hits several US states. BMJ 2010; 341:c4627.
85. Skurnik D, Merighi M, Grout M, et al. Animal and human antibodies to distinct Staphylococcus aureus antigens mutually neutralize opsonic killing and protection in mice. J Clin Invest 2010; 120: 3220-33.